ClinicalTrials.gg
RecruitingNCT07477431ALEVIATE-2Updated Jul 29, 2026

Levetiracetam for Persons at Risk for Alzheimer's Disease

A Phase 2 interventional study of Levetiracetam (LEV) and Placebo in Hippocampal Hyperactivation and Prodromal Alzheimer Disease, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 2 sites in Canada. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre — 8 open to participants now, 8 under way, 1 of them phase 3. Alzheimer Disease · Sunnybrook Health Sciences Centre.

Planned enrollment
4th of 13
40 · median 40
Started
2025
the only one that year
Phase 2
5 of 16
3 open now
Registered
15th of 16
by date

Among the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce elevated brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease (AD). The study is looking for people who are currently performing within normal limits on memory testing but who have one or more of the following risk factors for developing AD:

  1. People who feel like their memory is getting worse and who have a parent or sibling with Alzheimer's disease (dementia)
  2. People with two copies of the APOE E4 gene
  3. People who have tested positive for a biomarker of AD (e.g., blood p-tau test, brain amyloid PET scan)

During the screening period, a functional MRI (fMRI) scan of the brain will identify those participants who have the increased brain signaling that the study is looking to treat.

All participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill), but it will not be known what order they will receive them in. Participants will undergo cognitive testing, genetic testing, and several brain imaging scans as part of the study.

This is a pilot study, meaning that it is being carried out for the first time in a small number of participants. If the results show that treatment with LEV appears to be more beneficial than placebo in normalizing brain signaling, a larger study may follow.

This study is only being carried out in Toronto, Canada.

Read the detailed description

Changes in the brain associated with AD begin years before people start showing symptoms. One of these early changes involves an increase in brain signaling activity (hyperactivity) in the hippocampus (the memory area of the brain). This increase is similar to what is seen in epilepsy but on a smaller, unrecognizable scale.

Studies have found that small doses of an antiepileptic medication called levetiracetam (LEV) reduce this hippocampal hyperactivity in people with amnestic Mild Cognitive Impairment, the phase of AD when people first begin showing memory symptoms. The study aims to determine if this hyperactivity can be detected and treated even earlier, before individuals start showing any symptoms.

Participation begins with 3 screening visits that are a combination of questionnaires, cognitive tests, brain imaging, and collection of information on participant medical history, medications, and demographics.

If participant eligibility is confirmed after the screening visits, they are randomly enrolled in one of the study arms. There are two treatment periods, one period where participants receive the study drug and one period where they receive a placebo (a substance that looks like the study drug but does not have any active or medicinal ingredients). Half of the study participants will receive LEV first, then placebo, while the other half will receive placebo first, then LEV. This crossover study design allows all eligible enrolled individuals to receive the study drug at some point. The study is double-blinded, meaning that the participants and study staff will not be aware of when participants are receiving the drug.

From the day of consent, those participants who pass screening are expected to be in the study for approximately 6 months. Study procedures include cognitive testing, questionnaires, MRI Scans, EEG-MEG scans, physical and neurological exams, ECGs, blood sample collection for APOE genetic testing \& blood biomarker testing, optional blood sample collection for biobanking, and an amyloid PET scan.

This study is only being carried out in Toronto, Canada. Participants will be recruited at several Toronto sites, but most of the study visits (for all participants) will take place at Toronto Western Hospital, part of the University Health Network.

03

Conditions studied

  • Hippocampal Hyperactivation
  • Prodromal Alzheimer Disease

Browse trials for

Keywords

  • EEG-MEG
  • fMRI
  • Pattern Separation Task
  • PST
  • Levetiracetam
  • Crossover Design
  • AD
  • Prodromal AD
  • Hippocampal hyperactivation
  • Subjective cognitive complaints
  • Alzheimer Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to undergo all study procedures and has signed the form
  • Within normal limits on the (MoCA) at Screening
  • Age 55-85
  • Female participants must be (amenorrheic for at least 12 consecutive months without other known or suspected cause) or surgically sterile (bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy)
  • Sufficiently fluent in English to undergo cognitive testing, per investigator judgment
  • Increased risk of Alzheimer's disease, as indicated by one or more of the following:

    1. Participant has subjective cognitive complaints AND a family history of Alzheimer's disease (or of dementia suggestive of possible or probable Alzheimer's disease) in a first-degree relative; and/or
    2. Participant is known to be amyloid or tau positive; and/or
    3. Participant is known to be an APOE e4/e4 homozygote
  • Hippocampal hyperactivation, defined as activation >1.5 MAD above the median, during the pattern separation task (PST) on BOLD fMRI.

Exclusion criteria

Exclusion Criteria:

  • History of to levetiracetam or any other ingredients in the study drug or placebo.
  • Significant neurological disease, including but not limited to:

    1. Any type of cognitive impairment
    2. History of within 12 months of Screening
    3. History of seizures within 12 months of Screening
    4. Epilepsy
    5. Parkinson's disease
    6. Stroke (aside from subcortical lacunar infarcts)
    7. Multiple sclerosis
    8. Huntington's disease
    9. Normal pressure hydrocephalus
    10. Brain tumour (aside from benign tumours without mass effect, which are to be judged on a case-by-case basis)
    11. Subdural hematoma
    12. History of traumatic brain injury with persistent neurological deficits
    13. Known structural brain abnormalities
  • Significant or unstable psychiatric disease, including but not limited to:

    1. Schizophrenia
    2. Bipolar disorder
    3. Major depression which is not controlled in the opinion of the investigator
    4. Score ≥10 on the Geriatric Depression Scale (GDS) at Screening
    5. Presence of active suicidal ideation within the last 3 months as indicated by "yes" response to Question 4 or 5 on the Suicidal Ideation portion of the C-SSRS at Screening
    6. Answered "yes" to any of the suicide-related behaviours within the last 3 months on the Suicidal Behavior portion of the C-SSRS
    7. Hospitalized or treated for suicidal behavior within 5 years of Screening
    8. Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol in the opinion of the investigator
  • Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening).
  • Significant or unstable systemic illness or medical condition that would in the investigator's judgment make the participant unsuitable for inclusion in the study, including but not limited to:

    1. History of within 3 years of screening (except of basal or squamous cell carcinoma of the skin)
    2. Moderate-severe chronic kidney disease, , or congestive heart failure
  • Any of the following findings on a current (completed during screening) or previous brain MRI/CT scan:

    1. Severe white matter disease (Fazekas score66 = 3)
    2. Stroke involving a major vascular territory
    3. Subcortical lacunar infarcts >1.5cm in diameter
    4. Encephalomalacia
    5. Vascular malformations that are at high risk of hemorrhage
    6. Infective lesions
    7. Space-occupying lesions
    8. Any other abnormality that would in the opinion of the investigator make the participant unsuitable for participation in the study
  • Any to MRI or MEG (e.g., pacemaker, ferromagnetic metal implants, claustrophobia).
  • Treatment with the following medications at time of screening or while in the study:

    1. Anticonvulsant medications (unless taken for a different indication than seizures)
    2. Methotrexate
  • \<50ml/min/1.73m2 on screening bloodwork.
  • >470 msec (males) or >480 msec (females) on screening .
  • abnormal results on screening bloodwork that would in the opinion of the investigator make the participant unsuitable for inclusion in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Arm 1: Drug then Placebo

    Participants randomized to Arm 1 will receive LEV in Treatment Phase I and placebo in Treatment Phase II.

    Drug: Levetiracetam (LEV) · Other: Placebo

  • Other
    Arm 2: Placebo then Drug

    Participants randomized to Arm 2 will receive placebo in Treatment Phase I and LEV in Treatment Phase II.

    Drug: Levetiracetam (LEV) · Other: Placebo

Interventions

  • DrugLevetiracetam (LEV)

    Levetiracetam 125mg capsules BID for 28-35 days

  • OtherPlacebo

    Placebo capsules BID for 28-35 days

06

What researchers measure

Primary outcomes

  1. Level of fMRI activity in the hippocampus and entorhinal cortex during a pattern separation task (PST), as a function of LEV vs placebo

    Time frame: Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12)

Secondary outcomes

  1. Behavioural performance on the PST as a function of LEV vs placebo

    Evaluation of participant's ability to correctly discriminate between presented stimuli as old, new, or similar. The lure discrimination index (LDI) is based on the proportion of the presented lures correctly called similar and the proportion of lures incorrectly called old.

    Time frame: Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12)

  2. Frequency of epileptiform discharges on EEG as a function of LEV vs placebo

    Resting-state EEG

    Time frame: Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12)

  3. Power spectrum analysis for hippocampus in resting-state MEG as a function of LEV vs placebo

    Power in specific frequency bands (theta, alpha, beta) will be analyzed.

    Time frame: Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12)

  4. Changes in hippocampal signal in MEG during repetition suppression task as a function of LEV vs placebo

    Beta band power (desynchronization) will be measured with novel versus repeated presentation of images in the repetition suppression task.

    Time frame: Before and after each treatment phase (Screening/Baseline, Week 4, Week 8, Week 12)

Other outcomes

  1. Assessment of the relative safety and tolerability of LEV compared to placebo

    The number of adverse events and number of serious adverse events reported will be used to assess the safety of LEV compared to placebo.

    Time frame: Adverse events will be captured from randomization (Day 0) to study completion (Day 98-119).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Start date: two years after publication of the study results (main publication). No planned end date.

Access criteria: The data will be stored in controlled-access databases, for which access is limited to researchers who submit a study plan to the study publications and data sharing committee, and who sign an agreement to use the coded study data only for that research. The study will be listed in the GAAIN (Global Alzheimer's Association Interactive Network) registry once data becomes available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 26 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Mar 17, 2026
StartActual
Oct 23, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477431
Collaborators
University Health Network, Toronto, Weston Brain Institute
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Oct 23, 2025
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

ALEVIATE-2 Project Manager
Contact
aleviate-2@sunnybrook.ca
416-480-6100 ext. 63004
Sandra E. Black, MD, FRCP(C)
principal investigator · Sunnybrook Health Sciences Centre, University of Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion